One welcome development last year was a productive Food and Drug Administration, which approved more than 1,000 generic drugs and dozens of novel therapies. But FDA rejections can also be important for patients and innovation, and Commissioner Scott Gottlieb can prioritize a project that would add more public accountability to the approval process.

Mr. Gottlieb said in a speech last week that the agency is looking into releasing more information in “complete response letters,” the euphemism for FDA rejection notices. Under...  